Site search

Clear filter
2898 results for '' found
Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera (NCT05499013)
Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera (NCT05499013)
/
A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP) (NCT02821013)
/
Switching patients from intravenous to subcutaneous infliximab in inflammatory bowel disease (ACTRN12621001498886)
Switching patients from intravenous to subcutaneous infliximab in inflammatory bowel disease (ACTRN12621001498886)
/
A randomised double-blind placebo-controlled trial of topical sirolimus in chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients (NCT05860881)
/
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line
/
An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for
An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for
/
A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (NCT06012435)
A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (NCT06012435)
/
A Phase 2 Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Chronic Drug-Resistant Temporal Lobe Epilepsy (ACTRN12623000446662)
A Phase 2 Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Chronic Drug-Resistant Temporal Lobe Epilepsy (ACTRN12623000446662)
/
A Phase 2 Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Probable Progressive Supranuclear Palsy (ACTRN12620001254987)
A Phase 2 Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Probable Progressive Supranuclear Palsy (ACTRN12620001254987)
/
A Phase 2b Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Probable Behavioural Variant Fronto-temporal Dementia (ACTRN12620000236998)
A Phase 2b Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Probable Behavioural Variant Fronto-temporal Dementia (ACTRN12620000236998)
/
19 20 21 22 23